Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17130464 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Nascimento EB, et al. (2006) Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes 55, 3221-8 17130464
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T642-p - AS160 (human)
Orthologous residues
AS160 (human): T642‑p, AS160 iso3 (human): T154‑p, AS160 (mouse): T649‑p, AS160 iso2 (mouse): T649‑p, AS160 (rat): T651‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  diabetes mellitus, type 2 diabetes
 Relevant cell lines - cell types - tissues:  'muscle, skeletal'
 Cellular systems studied:  tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase

T246-p - PRAS40 (human)
Orthologous residues
PRAS40 (human): T246‑p, PRAS40 iso3 (human): T266‑p, PRAS40 (mouse): T247‑p, PRAS40 (rat): T247‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  diabetes mellitus, type 2 diabetes
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [InsR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase

S473-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [InsR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
 Cellular systems studied:  tissue
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
insulin increase
high-fat diet insulin inhibit treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

T649-p - AS160 (mouse)
Orthologous residues
AS160 (human): T642‑p, AS160 iso3 (human): T154‑p, AS160 (mouse): T649‑p, AS160 iso2 (mouse): T649‑p, AS160 (rat): T651‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [InsR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
 Cellular systems studied:  tissue
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
high-fat diet insulin inhibit treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

S21-p - GSK3A (mouse)
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', adipose tissue, heart, liver
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
high-fat diet insulin inhibit treatment-induced increase
high-fat diet increase
Associated Diseases
Diseases: Alterations: Comments:
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

S9-p - GSK3B (mouse)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', adipose tissue, heart, liver
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
high-fat diet insulin inhibit treatment-induced increase
high-fat diet increase
Associated Diseases
Diseases: Alterations: Comments:
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

T247-p - PRAS40 (mouse)
Orthologous residues
PRAS40 (human): T246‑p, PRAS40 iso3 (human): T266‑p, PRAS40 (mouse): T247‑p, PRAS40 (rat): T247‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  diabetes mellitus, type 2 diabetes
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [InsR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
insulin increase
high-fat diet insulin inhibit treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

S473-p - Akt1 (rat)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [InsR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
 Cellular systems studied:  tissue
 Species studied:  mouse, rat

T203-p - ERK1 (rat)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

Y205-p - ERK1 (rat)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

T183-p - ERK2 (rat)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

Y185-p - ERK2 (rat)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

T444-p - p70S6K (rat)
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

S447-p - p70S6K (rat)
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

T247-p - PRAS40 (rat)
Orthologous residues
PRAS40 (human): T246‑p, PRAS40 iso3 (human): T266‑p, PRAS40 (mouse): T247‑p, PRAS40 (rat): T247‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  diabetes mellitus, type 2 diabetes
 Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [InsR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
 Cellular systems studied:  cell lines, tissue
 Species studied:  human, mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.